Anti-vascular endothelial growth factor (anti-VEGF) therapy has become the first-line treatment for diabetic macular edema because the results of many randomized clinical trials have led to successful outcomes [1,2,3]. This evidence concerns the gene VEGFA and diabetic macular edema.